|Videos|January 23, 2023
Adjuvant Therapy Regimen Considerations for Patients with MIBC
Author(s)Matthew Galsky, MD
Dr Matthew Galsky explains the adjuvant therapy regimen he would have recommended for the patient with MIBC from the presented case, and whether patient preference factors into his decisions in clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5